1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
10
Active Trials
200 recruiting
5
Rare Diseases
across 8 areas
0
News (30d)
Quiet
BioRay Pharmaceutical Corp. is a company with 1 orphan drug designation across 5 rare diseases. Active clinical trials in 10 indications. gene therapy candidates in 1 disease. 19 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| gastric cancer | Recombinant anti-SIRPalpha humanized monoclonal antibody | Des.TrialAppr. |
| lupus erythematosus | - | Des.TrialAppr. |
| lymphoma | - | Des.TrialAppr. |
| sickle cell disease | - | Des.TrialAppr. |
| thalassemia | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
56
overlap in 2+ diseases
1/5
candidate diseases
0
avg importance: 0
19
affecting portfolio
0% of portfolio targets high unmet need diseases
56
overlap in 2+ diseases
1/5
candidate diseases
0
avg importance: 0
19
affecting portfolio